Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 2Biochemical Recurrent Prostate Cancer 1

Interventions

Specimen Handling 273Magnetic Resonance Spectroscopy 224pembrolizumab 214Carboplatin 173Biopsy 166Cisplatin 159Nivolumab 149Cyclophosphamide 133Radiotherapy 117Paclitaxel 117Gemcitabine 112Bevacizumab 92durvalumab 86Dexamethasone 80Rituximab 76Oxaliplatin 73atezolizumab 68Capecitabine 67venetoclax 66Fluorouracil 66Doxorubicin 65Docetaxel 65Etoposide 63Radiosurgery 60Radiation 57Prednisone 57Cytarabine 56Ipilimumab 55Pemetrexed 54Taxes 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Radium-223 × 90 days × Clear all
NCT05133440 2026-04-28

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
12 enrolled
Genitourinary

Prostatic Neoplasms

NCT02225704 2026-04-13

Radium-223 in Combination With Enzalutamide

Cancer Trials Ireland

Phase 2 Completed
45 enrolled
Genitourinary

Prostatic Neoplasms

NCT04206319 2026-03-16

Radium-223 in Biochemically Recurrent Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
19 enrolled
Genitourinary

Biochemical Recurrent Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡